Sponsored

Creso Pharma rolls out new hemp tea products using revolutionary technology

Source: © Saletomic | Megapixl.com

Summary

  • Creso Pharma has launched its three new hemp-derived tea products under the cannaQIX® brand.
  • The Company will sell the new CBD-based tea products to its existing distribution network in Switzerland.
  • Following the German Federal Court’s favourable decision, Creso is looking to launch its new tea products in Germany as well.

Creso Pharma Limited (ASX:CPH, FRA:1X8) has announced the rollout of its proprietary CBD-based tea products in Switzerland, with more European markets set aside for expansion.

The Company has launched three new tea products under its cannaQIX® brand. The hemp-based products include cannaQIX® NITE tea, cannaQIX® tea, and cannaQIX® Immunity tea.

Creso’s ground-breaking technological achievement

The latest products have been manufactured based on a new 2nd generation pioneering technology. This technology is focused on improving the CBD content in compliance with regulations and gives the products a better taste.

The development of the new products is an inventive technological achievement for Creso.  Besides, the new technology provides a significant competitive advantage to the Company.

Creso will now advance this new revolutionary technology for the manufacturing of cannaQIX® lozenges in the future.

Source: CPH Announcement, 1 April 2021

MUST READ: Double bonanza: Creso eyes OTC listing; Halucenex gets new psilocybin supplies

Leveraging established distribution network

Creso Pharma has completed all the necessary legal and regulatory due diligence, and the Company can now legally market and sell its new CBD-based tea products throughout Switzerland.

This will also leverage Creso’s established distribution network, which comprises more than 2,100 points of sales in Switzerland, where the Company is already selling its cannaQIX® products. The distribution networks include pharmacies, health nutrition shops, pharmacy networks, and major retail groups, including Manor.

Notably, Creso Pharma also supplies its products to all major wholesalers in Switzerland, including Amedis, Galexis, and Voigt. The distribution networks provide Creso with an established footprint that de-risks the new products’ rollout substantially.

DID YOU KNOW: Creso Pharma eyes first-mover advantage in psychedelics space as Halucenex signs new deal

CPH eyes launch of new hemp tea products in Germany

Recently, Germany’s Federal Court of Justice announced the decision to annul previous charges against hemp tea sellers. The charges had temporarily delayed the launch of Creso’s new tea products in Germany, scheduled for Q3 2020.

However, the Federal Court’s decision has cleared the path for the Company to launch its new tea products in Germany. The favourable decision has removed ambiguity regarding the guidelines related to the sale of food products based on hemp flowers and leaves in Germany. Now, CPH anticipates actively marketing and selling its CBD-based tea products in Germany without any regulatory obstacles.

Entry in other European markets

Interestingly, on the successful rollout of its new cannaQIX® products in both countries, the Company will explore the new expansion opportunities to introduce its products into other European markets. Creso Pharma will undertake the required due diligence for the sale legality in each new jurisdiction, in line with its standard practices.

Furthermore, CPH anticipates that consumers will well accept its new hemp-derived tea products.

Commenting on the launch, Commercial & Development Director of Creso, Dr Gian Trepp, said:

Creso Pharma is well financed to expand its proprietary technologies into new verticals, with other significant initiatives and revenue-generating products for human and animal health currently under development. The Company anticipates launching additional products shortly.

On 7 April 2021, CPH shares were trading at A$0.200 (at AEST 12:33 PM).

ALSO READ: Creso Pharma (ASX:CPH) raises A$18M to scale up operations, fund trials


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK